Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 2/20 | 0.36 |
| ▸ | WNT1 | P04628 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2318020 | 0.85 | TSHR (0.56) | CDK5CDK5R1KMT2AMEN1POLB | |
| SCHEMBL2317358 | 0.84 | NPY5R (0.49) | GSK3BDYRK1AWNT1 | |
| SCHEMBL2317308 | 0.80 | DYRK1A (0.42) | DYRK1ACDK5CDK5R1KMT2AMEN1 | |
| SCHEMBL2315654 | 0.77 | NPY5R (0.61) | GSK3BDYRK1AWNT1 | |
| SCHEMBL25131042 | 0.76 | KDM4E (0.56) | GSK3BDYRK1APOLBALDH1A1WNT1 | |
| SCHEMBL2418168 | 0.75 | POLB (0.45) | KMT2AMEN1HTTRIOK2POLB | |
| SCHEMBL25131750 | 0.75 | POLB (0.45) | GSK3BDYRK1ACDK5CDK5R1KMT2A | |
| SCHEMBL2418162 | 0.75 | POLB (0.45) | KMT2AMEN1HTTRIOK2POLB | |
| SCHEMBL27007142 | 0.74 | ALDH1A1 (0.54) | KMT2AMEN1HTTRIOK2POLB | |
| SCHEMBL2320292 | 0.74 | ALDH1A1 (0.51) | KMT2AHTTRIOK2POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2352730-A2 | BIOLOGICALLY ACTIVE AMIDES | H. Lundbeck A/S (DK) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010053861-A2 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | NPY5R, NPY1R, NPY2R | GSK3B 2646/4885DYRK1A 1159/4885CDK5 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.